Correlations between HER2 expression and other prognostic factors in breast cancer: Inverse relations with the Ki-67 index and P53 status by Payandeh, M. et al.
Asian Pacific Journal of Cancer Prevention, Vol 17, 2016 1015
DOI:http://dx.doi.org/10.7314/APJCP.2016.17.3.1015
Inverse Correlations between HER2 Expression with the Ki-67 Index and P53 Status in Breast Cancer Cases in Iran
Asian Pac J Cancer Prev, 17 (3), 1015-1018
Introduction
Breast cancer (BC) is the most frequent malignancy 
among women and can be a leading cause of death 
through middle-aged women that adjuvant chemotherapy, 
commonly include alkylating agents and anthracyclines, 
improves survival rate in operable BC (Payandeh et al., 
2015a). Recent attention has been directed singularly 
at molecular classifications of BC (Carey et al., 2006). 
Human epidermal growth factor receptor-2 (HER2) is a 
marker of poor prognosis in BC (Ménard et al., 2001). 
Most studies performed to evaluate the HER2 status 
were conducted in western countries and compared 
prognostic value of HER2 in anthracyclines-based to non 
anthracyclines-based regimens. 
In different studies performed in a number of countries, 
HER2 amplification was found in 20-30% of breast 
malignancies (Fountzilas et al., 2012), but in some countries 
such as Lebanon the higher percentage was reported (el 
AT et al., 2000). The factors investigated included the 
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Abstract
 Background: Overexpression or amplification of human epidermal growth factor receptor-2 (HER2) is 
associated with grade of malignancy and a poor prognosis in breast cancer (BC). The aim of this study was to 
evaluate of value of HER2 as a prognostic marker, and to analyze associations with common histopathological 
parameters in BC cases. Materials and Methods: Between of 2007 to 2014, 260 patients with BC referred to 
Oncology Clinic provided cancer tissue samples which underwent immunohistochemistry (IHC) for markers. 
ER and PR positivity was defined as ≥10% positive tumor cells with nuclear staining. HER2-positive was 
defined as either HER2 gene amplification by fluorescent in situ hybridization (FISH) or scored as 3+ by IHC. 
For HER2 (2+), FISH was performed to determine HER2 positivity. Results: The mean age at diagnosis for the 
patients with HER2-negative was significantly higher than in HER2-positive cases. Also, there were significant 
correlations between histological grade, nuclear grade, lymph node metastasis, tumor size, ER status, PR status, 
p53 overexpression and Ki-67 index with HER2 expression. HER2-negative lesions were of higher grade and 
more likely to be ER-negative, PR-negative, p53-positive, lymph node metastasis, with a tumor size<2cm and 
also Ki-67≥20% as compared to the HER2-positive group. Conclusions: Contrary to the results of other studies, 
HER2-positive tumors in our study had a lower Ki-67 index and were p53-positive. Also, Ki-67 proliferation 
index ≥20% in more studies was associated with p53-positive.Therefore, tumors which are HER2-positive and 
have a Ki-67≥20% had a more aggressive behavior compared to HER2-positive and Ki-67<20% lesions. 
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presence or absence of lymph node metastasis, nuclear 
grade, ER/PR status, proliferation (Ki-67), HER2 and p53 
overexpression. Immunostaining for ER, PR, p53, Ki-67 
and HER2 was carried out as previously described (Kai 
et al., 2006). Ki-67 is present in all proliferating cells, and 
there is great interest in its role as a proliferation marker 
(Nishimura et al., 2010). The proliferation marker Ki-67 
is one of the most controversially discussed parameters 
for treatment decisions in breast cancer patients (Inwald 
et al., 2013). The prognostic impact of HER2 positivity 
is reported to be lower in lymph node-negative compared 
with node-positive women (Ménard et al., 2001). BC 
aggressiveness can be correlated with proliferation status 
of tumor cells, which can be ascertained with refernce to 
tumor grade as well as in terms of the Ki67 index (Haroon 
et al., 2013).
The purpose of this study was to evaluate of value 
of HER2 as a prognostic marker, and to analyze the 
associations between HER2 and common histopathological 
parameters in breast cancer.
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Materials and Methods
Patients
Between 2007 to 2014, 260 patients with BC referred 
to Oncology Clinic in Kermanshah city, Iran. We analyzed 
age, sex, grade, tumor size, vascular invasion, hormone 
receptors status, p53 overexpression, Ki-67 index in the 
patients. A sufficient sample size was selected from any 
patient and the slides were stained by hematoxylin and 
eosin method. Then 4-micron sections were prepared for 
staining with H & E for IHC markers (Ki-67, ER, PR, 
p53 and HER2). ER and PR positivity was defined as 
≥10% positive tumor cells with nuclear staining. HER2-
positive was defined as either HER2 gene amplification 
by fluorescent in situ hybridization (FISH) or scored as 
3+ by IHC (Ahmadi et al., 2015). For HER2 (2+), FISH 
was performed to determine HER2 positivity. Age, tumor 
size, lymph node involvement, histological grade, nuclear 
grade, vascular invasion, p53 and Ki-67 index were other 
factors that determined in a lot of patients. Ki-67 index 
was divided to scores (<20% and ≥20%). 
Statistical analysis
The correlation between the variables was done 
by IBM SPSS statistics 19. Chi-square test was used 
to analyze the significance of correlation between the 
expression of HER2 and other parameters and P <0.05 
was considered significant. 
Results 
The Table 1 shows correlation between the number 
of variables with HER2 expression in NHL patients. 
The mean age at diagnosis for the patients with HER2-
negative was higher than HER2-positive and this 
correlation was significant (P=0.012). Also, there was 
significant correlation between histological grade, nuclear 
grade, lymph node metastasis, tumor size, ER status, PR 
status, p53 overexpression and Ki-67 index with HER2 
expression. The patients with HER2-negative were more 
with higher grade and also percentage of patients with 
ER-negative, PR-negative, p53-positive, lymph node 
metastasis, tumor size<2cm and Ki-67≥20% were more 
in HER2-negative group vs. HER2-positive group.
We divided HER2-positive patients to two groups 
based on Ki-67 index (HER2-positive and Ki-67<20% 
(group 1) vs. HER2-positive and Ki-67≥20% (group 2)) 
(Table 2). There was just significant correlation between 
two groups for ER status and p53 overexpression. 
Figure 1. Numbers of patients with Breast Cancer 
(HER2-positive vs. HER2-negative) Based on Age 
Groups
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Figure 2. Numbers of Patients with Breast Cancer 
(HER2-positive and Ki-67<20% vs. HER2-positive 
and Ki-67≥20%) Based on Age Groups
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Table 1. Correlation between Baseline Characteristics 
of breast cancer patients and HER2 expression (n=260)
Variables HER2-positive€ HER2-Negative€ P-value≠
Age, year   
      Mean 45.9 48.8 0.012
      Range 24-73 26-82
      >50 35(33%) 63(40.9%) 0.123
      ≤50   71(67%) 91(59.1%) 
Histological grade, n=237   
0.000
      Ι 15(14.9%) 32(23.5%)
      ΙΙ 77(76.2%) 63(46.3%)
      ΙΙΙ 9(8.9%) 41(30.1%)
Nuclear grade, n=152   0.000
     Ι 14(21.9%) 21(23.9%)
     ΙΙ 49(76.6%) 41(46.6%)
     ΙΙΙ 1(1.6%) 26(29.5%) 
Lymph node metastasis, n=242  0.003
      Yes 74(74.7%) 81(56.6%)
      No 25(25.3%) 62(43.4%)
Tumor size (cm), n=243  0.018
      ≥2 93(91.2%) 114(80.9%)
      <2 9(8.8%) 27(19.1%)
Vascular invasion, n=206  0.129
      Yes  60(70.6%) 75(62%)
      No 25(29.4%) 46(38%)
ER   0.000
      Positive 77(72.6%) 79(51.3%)
      Negative 29(27.4%) 75(48.7%)
PR   0.006
      Positive 71(67%) 78(50.6%) 
      Negative 35(33%) 76(49.4%) 
P53, n=231   0.001
      Positive 30(32.3%) 74(53.6%)
      Negative 63(67.7%) 64(46.4%)
Ki-67   0.006
      <20% 69(65.1%) 75(48.7%)
      ≥20% 37(34.9%) 79(51.3%)
All p-values were calculated by Chi-square test, except for mean age 
was with T-test. € IHC 0, 1+ and 2+ FISH negative were regarded as 
negative while IHC 3+ or 2+ FISH positive were regarded as positive
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Therefore, PR-negative or p53-positive was more in group 
1 compared with group 2. 
Figure 1 and Figure 2 show the prevalence of patients 
with BC based on age group. The most percentage of 
patients is located in 46-50 years.
Discussion
Invasive breast carcinoma is the most common 
malignant tumor in women worldwide that trastuzumab 
therapy (Herceptin) use for breast tumors with HER2 
overexpression (Payandeh et al., 2015b). HER2 belongs 
to a family of four transmembrane receptors involved in 
signal transduction pathways that regulate cell growth 
and differentiation. Overexpression or amplification of 
HER2 is associated with malignancy and a poor prognosis 
in BC (Yarden Y,2001). HER2-positive BCs tended 
to be larger and were less likely to express estrogen 
receptors, and the incidence rate was higher in patients 
less than 40 years old (Swede et al., 2001). In our study, 
HER2-positive BCs occurred more in 46 to 50 years. 
A retrospective study assessed HER2-positive patients 
who were diagnosed with brain metastases. The median 
age of the 432 patients was 54 years (range, 20-86 years) 
(Hayashi et al., 2015). Our study showed that in patients 
with HER2-positive or HER2-negative, the mean age 
was higher than 45 years. Camerini et al.(2011) reported 
that HER2 expression had not correlation with age, ER 
expression, PR expression, Ki-67 and just had with grade. 
A research (Shokouh et al., 2015), showed that significant 
correlation was observed between tumor grade with HER2 
overexpression. Higher grades had significantly greater 
positivity in Ki-67 index and HER2-positive tumors had 
a higher Ki-67 index. Moreover, in young patients with 
breast carcinoma tumors, the rates of Ki-67 with the 
overexpression of HER2 and p53 mutations are higher, 
and it shows a more aggressive behavior than other 
tumors (Shokouh et al., 2015). The Ki-67 expression was 
associated significantly with histological grade, ER, PR, 
HER2, and p53 status (Li et al., 2014). A higher Ki-67 
index (≥20%) significantly correlated with a higher grade 
of malignancy, such as negative ER/PR, higher grade, 
p53 overexpression and HER2- positive (Nishimura et 
al., 2010). Wiesner et al. (2009) reported that a Ki-67 
proliferation index ≥20% was found to be associated with 
all prognostic factors such ER, PR, HER2 and nuclear 
grade. High p53 expression was positively correlated 
with HER2 score and Ki-67 expression (Yamamoto et al., 
2014). HER2 positivity was detected more significantly in 
patients with p53 overexpression (Lee et al., 2011). There 
was no significant correlation between HER-2 and age, 
tumor size, lymph node status, ER, and PR. There was 
significant correlation between HER-2 with tumor grade 
and p53 (Patnayak et al., 2015). In our study, there was 
significant correlation between histological grade, nuclear 
grade, lymph node metastasis, tumor size, ER status, PR 
status, p53 overexpression and Ki-67 index with HER2 
expression. HER2 inversely correlated with higher grade, 
higher Ki-67 index (≥20%) and p53 positively and also 
directly with ER expression, PR expression, lymph node 
metastasis, lower tumor size. Also, in HER2-positive, 
patients with Ki-67≥20% had significantly higher ER 
expression and p53-positive compared to HER2-positive 
and Ki-67<20% had higher p53-positive.
In conclusions, Contrary to the results of other studies, 
HER2-positive tumors in our study had a lower Ki-67 
index and p53-positive. Also, Ki-67 proliferation index 
≥20% in more studies associated with p53-positive.
Therefore, tumors with HER2-positive and Ki-67≥20% 
had a more aggressive behavior compared to HER2-
positive and Ki-67<20%.
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